Transplacental effect of lead compounds on tissue plasminogen activator activity, plasminogen activator inhibition and plasmin inhibition.
The transplacental effect of lead compounds (lead acetate and tetraethyl lead) on the tissue plasminogen activator activity (PAA), plasminogen activator inhibition (PAI) and plasmin inhibition (PI) was studied in the rat. The concentration of lead in organs of the newborn showed a great variation; the distribution of lead in the organs studied depended on the dose and the stage of gestation at injection. In each organ the concentration of lead was dose-dependent. In control specimens no lead could be detected. The tissue response of PAA, PAI and PI to the lead compounds also showed a great variation; however, there was no correlation between lead concentrations and PAA, PAI or PI responses. Changes of one or more of the parameters studied (PAA, PAI or PI) were noticed in lungs, liver, heart, brain and kidneys. The PAA was due to the tissue type plasminogen activator in all organs studied; in kidneys and lungs the urokinase type of plasminogen activator was also detected. Therefore, fetal tissue PAA, PAI and PI can be affected transplacentally by lead compounds.
Smokovitis
A
A
Department of Physiology, Faculty of Veterinary Medicine, Aristotelian University, Thessaloniki, Greece.
Kokolis
N
N
Alexaki
E
E
Tsafaris
F
F
D000818:Animals; D000831:Animals, Newborn; D005260:Female; D005341:Fibrinolysin / Q000378:metabolism*; D008297:Male; D008431:Maternal-Fetal Exchange; D009928:Organ Specificity; D009942:Organometallic Compounds / Q000493:pharmacokinetics*; D010960:Plasminogen Activators / Q000378:metabolism*; D011247:Pregnancy; D051381:Rats; D011919:Rats, Inbred Strains; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism
D009942:Organometallic Compounds; D010960:Plasminogen Activators; D005341:Fibrinolysin; D014568:Urokinase-Type Plasminogen Activator; C008261:lead acetate